Acute Myeloid Leukemia Trials in fairway, united states
Conditions / Acute Myeloid Leukemia / fairway, united states
Research into Acute Myeloid Leukemia spans multiple therapeutic approaches and trial phases.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | RECRUITING | PHASE2 |
| NCT05554393 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | RECRUITING | PHASE2 |
| NCT05554406 | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | RECRUITING | PHASE2 |
| NCT03850535 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | TERMINATED | PHASE1/PHASE2 |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | TERMINATED | PHASE3 |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | RECRUITING | PHASE1 |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | RECRUITING | PHASE1 |
| NCT01546038 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | COMPLETED | PHASE2 |
| NCT06317649 | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | RECRUITING | PHASE2 |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | ACTIVE_NOT_RECRUITING | PHASE2 |